- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00408915
Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion
Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current CALIPSO study investigates the efficacy of a continuous lisuride infusion against the optimized previous oral therapy in patients experiencing motor fluctuations with OFF periods and/or strenuous dyskinesias of more than four hours per day.
The controlled core study is scheduled to last six weeks. Within the study the previous oral therapy will either be continued in a capsule/blinded design (while a placebo infusion is going on concurrently) or the oral therapy is substituted by lisuride infusion (while placebo capsules are administered at the same time).
After the controlled core study all patients whose condition has not worsened during the study (meaning those patients of the placebo infusion group as well, who were treated during the core study just as they were before), will be given the chance to continue with the infusion therapy with lisuride in an open extension phase.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nuremberg, Germany
- IMEREM GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Idiopathic Parkinson's disease for at least 3 years (diagnosis based on the UK Brain Bank Criteria)
- Presence of motor fluctuations (wearing-off or other "OFF" periods) and / or presence of troublesome dyskinesia, with a total daily minimum of at least 4 hours, despite optimized oral anti-parkinsonian therapy
- Stable levodopa intake, i.e. at least four doses of levodopa per day
- Stable dosing of all other anti-parkinsonian drugs, such as dopamine agonists, COMT- and MAO-B inhibitors, amantadine, or anticholin-ergics for a minimum of four weeks prior to inclusion.
- The following oral dopamine agonist drugs are allowed in this trial: pramipexol up to a total daily dose of 3,15mg, ropinirol up to a total daily dose of 24mg, cabergoline up to a total daily dose of 6mg or combinations Concomitant diseases are stable and well controlled Willingness and ability to comply with all trial requirements Written informed consent
Exclusion Criteria:
- Non-idiopathic Parkinson's disease (e.g. drug-induced or other forms of secondary or atypical parkinsonism such as MSA)
- Significant neurological symptoms not accounted for by Parkinson's disease
- History or presence of dementia demonstrated by the Mini-mental status examination (MMSE < 24)
- Presence of major depression according to DSM IV criteria (≥ 6 months)
- History or presence of epilepsy
- Presence of dopaminergic psychosis
- Unstable severe concomitant diseases (e.g. liver diseases, kidney diseases or clinically relevant cardiac or coronary dysfunction)
- Presence of heart valvular fibrosis or indication of significant valvular stenosis / insufficiency on echocardiogram
- History of syncope and/or severe or otherwise symptomatic orthostatic hypotension
- Present treatment with neuroleptics, including atypical neuroleptics
- Treatment with other CNS active drug therapy (e.g. sedatives, hypnotics, anti-depressants, anxiolytics) unless the dose has been stable for at least four weeks prior to the baseline visit
- Participation in another trial of an investigational drug within the last 28 days or current participation in another trial of an investigational drug
- Clinically significant laboratory abnormalities
- Previous neurosurgery for Parkinson's disease
- Alcohol or drug abuse in the past three years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Change from baseline B0 to T6 in total daily "OFF-time and ON-time with troublesome dyskinesia
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary objectives are to evaluate quality of life, quality of sleep, UPDRS Score
|
clinical global impression, safety and tolerability.
|
After the double-blind period, long-term efficacy of lisuride will be assessed for further 2 years in an open-label extension of the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: J. Winkler, Professor, Klinik und Poliklinik für Neurologie der Universität Regensburg
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Serotonin Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin Receptor Agonists
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Lisuride
Other Study ID Numbers
- CALIPSO
- EudraCT Number:
- 2005-001006-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Continuous Subcutaneous Lisuride Infusion
-
The University of The West IndiesNot yet recruitingOverweight or Obese Women, Elective Lower Segment Cesarean Section
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
National Center for Research Resources (NCRR)CompletedPregnancyUnited States
-
University Hospital Schleswig-HolsteinGerman Research Foundation; University of Luebeck; Roche DiagnosticsCompletedPsychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM) (pumpkin)Diabetes Mellitus, Insulin-DependentGermany
-
Mongi Slim HospitalCompletedEpidural; AnalgesiaTunisia
-
Federico II UniversityTerminatedDiabetes Mellitus | Covid19Italy
-
King's College LondonUniversity Hospital, Caen; University of LeicesterCompletedDiabetes Mellitus, Type 2
-
First Affiliated Hospital of Guangxi Medical UniversityRecruiting
-
Boehringer IngelheimCompletedSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in PsoriasisPsoriasisUnited States, Germany
-
Massachusetts General HospitalBaxter Healthcare CorporationCompletedDehydration | Mass Casualty IncidentUnited States